Ovarian xenotransplantation could offer hope for rare species
27 September, 2002 by Melissa TrudingerXenotransplantation of ovarian tissue from endangered species may allow zoologists and conservationists to propagate endangered animals, according to a paper published today in the journal Science.
Genesis beefs up strategic development with new hiring
27 September, 2002 by Graeme O'NeillNew Zealand's Genesis Research and Development Corporation has persuaded long-serving director Dr Douglas Williams to join the company as head of its new strategic development unit, as part of its plan to make hay while it waits for the sun to rise again on the biotech industry.
Global gene guild gets the buzz on pesticide resistance
27 September, 2002 by Graeme O'NeillIt seems that globalisation works for genes too. Over the past half century, a global guild of the geneticist's favourite fruit fly, Drosophila melanogaster, has been using science's global networks to smuggle a souped-up, multi-purpose survival kit to its six-legged subscribers.
Axon aiming to seal J&J deal
26 September, 2002 by Pete YoungListed drug discovery instrumentation maker Axon Instruments is aggressively pursuing final-stage development of an ion channel drug discovery platform in collaboration with Johnson & Johnson Pharmaceutical Research & Development (J&JPRD).
Local scientists slam UK anti-GM report
26 September, 2002 by Melissa TrudingerScientists have criticised a new report -- Seeds of doubt: North American farmers' experiences of GE crops -- released by the Soil Association, the UK's main campaigning organisation for organic farming.
Promics progresses with BIF money
25 September, 2002 by Pete YoungA $216,800 government grant to Promics is the latest piece of good news for the young biotech and its anti-inflammatory drug candidate PMX53.
GM cotton gains Australian approval for commercial release
25 September, 2002 by Melissa TrudingerThe OGTR has approved Monsanto's application for commercial release of its GM cotton varieties in some areas.
New chairman of the board for Gradipore
23 September, 2002 by Melissa TrudingerGradipore has appointed Australian businessman Jeremy Davis as its new chairman of the board.
Smelling a rat
23 September, 2002 by Pete YoungTrapped in the political crossfire of the stem cell debate, biotech industry icon Prof Alan Trounson has taken some heavy hits.
Thinking big? Think US, advises new Biota chief
23 September, 2002 by Melissa TrudingerThe single most important thing an Australian biotechnology company can do to increase its chances of success, according to new Biota Holdings CEO Peter Molloy, is to be on the ground in the US.
NZ biotech A2 study links milk, heart disease
23 September, 2002 by Melissa TrudingerA link between heart disease and the consumption of milk protein beta casein A1 has been demonstrated in a study performed by Queensland researchers for New Zealand biotech company A2 Corporation.
Progen to license cancer R&D
18 September, 2002 by Pete YoungDrug developer Progen Industries is licensing development rights to a new patented cancer therapy from the University of New South Wales.
BioProspect at the crossroads
18 September, 2002 by Pete YoungA biotech company in the forefront of mining Australia's natural biodiversity for blockbuster commercial applications is approaching its moment of truth.
Financial agreement takes the pressure off for pSivida
18 September, 2002 by Pete YoungPorous silicon drug delivery company pSivida has received a multimillion dollar vote of confidence in its prospects from New York's GEM private equity group.
Biotech sector looking OK, say analysts
17 September, 2002 by Melissa TrudingerASX-listed biotechs released a flurry of final results last week, with most companies meeting expectations for expenditure, revenues and losses.
